Research and Collaboration Arrangements - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue		$ 1,960,000	$ 5,090,000
Revenue recognized		3,100,000	15,100,000
Accounts receivable		0	47,000
uniQure
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue		566,000	3,661,000
Accounts receivable		0	0
uniQure | uniQure Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement, initial research term	3 years
Upfront payments received	$ 200,000
Options to purchase ordinary shares	609,744
Ordinary shares vesting period	3 years
Fair value of options	$ 10,600,000
Fair value of non monetary consideration of intellectual property right				$ 5,100,000
Increase in revenue recognized related to performance obligations partially satisfied in the beginning of the current year		2,200,000
uniQure | uniQure Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payments entitled to receive for achievement of research and development milestones	$ 5,000,000.0
uniQure | Amended uniQure Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payments eliminated				$ 5,000,000.0
uniQure | Amended uniQure Agreement and Second uniQure Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		3,100,000	700,000
Remaining performance obligations		$ 600,000	$ 3,700,000